Maryland Prescription Drug Affordability Chair Van T. Mitchell, shown here in a May 2024 meeting of the board in Annapolis. (Photo by Danielle J. Brown/Maryland Matters).
After months of deliberation, information gathering and public testimony, a state board unanimously agreed Monday that two common medications for type-2 diabetes and other conditions appear to pose an affordability challenge to the state and Marylanders.
The state Prescription Drug Affordability Board approved two resolutions saying that prescription drugs Jardiance and Farxiga likely pose an “an affordability challenge for the state health care system” and the state should look for ways to bring down those costs…